Pregabalin is a Schedule V gabapentinoid with a discontinuation syndrome that is more consistently reported, more rapid in onset, and more likely to include seizure risk than its structural cousin gabapentin. Prescribers increasingly encounter pregabalin dependence in patients treated long-term for neuropathic pain, fibromyalgia, or generalized anxiety disorder (an off-label indication in the US, approved in the EU), and abrupt discontinuation — whether due to nonadherence, hospitalization, or insurance lapse — carries meaningful clinical risk. This article reviews pregabalin's pharmacokinetics, the evidence base for its withdrawal syndrome, and a dose-dependent tapering protocol.

Pharmacokinetics relevant to tapering

Pregabalin has a short elimination half-life of approximately 6.3 hours in patients with normal renal function, with steady state reached within 24–48 hours of a stable dosing regimen. It is not hepatically metabolized and has no active metabolites; more than 90% is excreted unchanged renally. This has two direct implications for tapering:

No metabolite buffering. Unlike drugs with active metabolites that extend the effective half-life (e.g., fluoxetine's norfluoxetine), pregabalin's plasma concentration falls in near-linear proportion to dose reduction, with no pharmacokinetic "cushion." Symptom onset after a dose reduction is typically within 24–48 hours.
Renal function dictates clearance. In patients with creatinine clearance (CrCl) below 60 mL/min, elimination half-life is prolonged and dose reduction increments should be spaced further apart, with total daily dose recalculated per the existing renal dosing table (CrCl 30–60: reduce total daily dose by half; CrCl 15–30: reduce to one-quarter; CrCl <15: further reduction and once-daily dosing).

Available formulations are immediate-release capsules and oral solution (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg) and an extended-release tablet (Lyrica CR, 82.5 mg and 165 mg), approved only for neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, dosed once daily with a meal. The IR-to-CR conversion is not 1:1 by tablet strength; CR labeling specifies a separate titration schedule, and tapering an established CR regimen should use CR strengths rather than converting to IR mid-taper unless clinically necessary.

The discontinuation syndrome: what the evidence shows

Pregabalin discontinuation symptoms were documented in the original pivotal trials and are now well characterized in postmarketing pharmacovigilance and observational cohorts.

Symptom profile. The most frequently reported symptoms across studies are insomnia, nausea, headache, diarrhea, anxiety, hyperhidrosis, and — less commonly but of highest clinical concern — seizures, including in patients with no prior seizure history. A 2013 systematic review by Guglielmo et al. and the FDA-approved labeling both note that discontinuation symptoms occurred in up to 12–16% of pregabalin-treated patients in placebo-controlled trials who received the drug for as little as several weeks, with onset generally within the first 24–48 hours after the last dose and duration typically 1–2 weeks, though a persistent minority report protracted symptoms lasting months.

Dose-response relationship. Discontinuation symptom incidence and severity scale with total daily dose and, to a lesser extent, treatment duration. Patients on doses at or above 300 mg/day and those treated for longer than 12 months show substantially higher rates of moderate-to-severe discontinuation symptoms in cohort data reviewed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor, 2024), which extend hyperbolic tapering principles — originally developed for antidepressants and benzodiazepines — to gabapentinoids on the basis of shared GABAergic and calcium channel modulation mechanisms.

Seizure risk specifically. Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Abrupt cessation, particularly at higher doses, can produce a rebound hyperexcitability state. The FDA label for Lyrica carries a specific discontinuation warning: taper over a minimum of 1 week when discontinuing, regardless of indication, due to reported cases of seizure — including in patients without epilepsy — following abrupt withdrawal. This is a labeled, not merely observational, risk.

Differentiating withdrawal from relapse. In patients treated for neuropathic pain or fibromyalgia, distinguishing withdrawal-related paresthesia and myalgia from disease recurrence requires attention to timing: withdrawal symptoms cluster within days of a dose reduction and typically resolve or plateau within 1–2 weeks, whereas pain relapse tends to build more gradually and does not remit spontaneously. In GAD, rebound anxiety from discontinuation is often difficult to distinguish from underlying illness recurrence without a prior treatment history for reference; a slower taper reduces this diagnostic ambiguity by lowering peak symptom intensity.

Suggested taper schedule

There is no FDA-mandated taper rate beyond the minimum 1-week discontinuation window; the following schedule reflects a synthesis of the Maudsley Deprescribing Guidelines' hyperbolic approach and typical clinical practice for patients on stable long-term therapy. It should be adjusted for renal function, dose, treatment duration, and individual tolerance.

| Total daily dose | Suggested reduction increment | Suggested interval between reductions | ||---| | >450 mg/day | 25–50% of current dose | 2–4 weeks | | 150–450 mg/day | 25% of current dose | 2–4 weeks | | 50–150 mg/day | 25 mg (or ~10–25% of current dose) | 2–4 weeks | | <50 mg/day | 25 mg or smallest available decrement | 4 weeks, extending as needed |

For patients with a history of significant discontinuation symptoms, prior seizure activity, or doses above 450 mg/day, a slower protocol — reducing by 10% of the current dose every 2–4 weeks rather than fixed percentage cuts — produces smaller absolute reductions as the dose falls, consistent with hyperbolic tapering logic and receptor occupancy curves that flatten at lower doses. This requires compounding or oral solution for increments below the smallest capsule strength (25 mg).

Minimum taper duration for acute/inpatient settings: at least 1 week, per FDA labeling, split into at least two step-downs rather than a single discontinuation.

Minimum taper duration for long-term outpatient use (>3 months, especially >300 mg/day): several weeks to a few months; patients on doses above 450 mg/day for over a year may require 3–6 months for a low-symptom taper.

Example: tapering from 300 mg/day (150 mg BID)

Week 0: 300 mg/day → 225 mg/day
Week 2–4: 225 mg/day → 150 mg/day
Week 4–8: 150 mg/day → 100 mg/day
Week 8–12: 100 mg/day → 50 mg/day
Week 12–16: 50 mg/day → 25 mg/day
Week 16–20: 25 mg/day → discontinue

Dosing should remain divided (BID or TID) throughout the taper given the short half-life; consolidating to once-daily dosing before the total daily dose is low risks larger peak-trough swings and increased breakthrough symptoms.

Distinguishing pregabalin from gabapentin in taper planning

Although both are gabapentinoids and share a discontinuation symptom profile, pregabalin's linear, saturable-transporter-independent absorption (versus gabapentin's dose-dependent, saturable absorption via the LAT1 transporter) means pregabalin's exposure scales predictably with dose, while gabapentin's does not. This makes percentage-based tapering more pharmacokinetically valid for pregabalin than for gabapentin, where equivalent percentage dose reductions at high doses may produce disproportionately large drops in plasma exposure due to absorption saturation. Do not assume a gabapentin taper protocol transfers directly to pregabalin dosing logic.

Special populations

Concurrent opioid or benzodiazepine use. Pregabalin is frequently co-prescribed with opioids or benzodiazepines, and additive CNS/respiratory depression is a recognized risk (FDA boxed warning language for concomitant use). When tapering pregabalin in a patient on concurrent CNS depressants, taper one agent at a time where clinically feasible to isolate the source of any emergent symptoms and avoid compounding withdrawal syndromes.
Renal impairment. As above, extend intervals between reductions in proportion to reduced clearance; a patient with CrCl 30 mL/min should be assumed to require roughly double the standard interval between dose steps.
Pregnancy. Pregabalin crosses the placenta; abrupt discontinuation risking maternal seizure must be weighed against continued fetal exposure on an individualized basis in consultation with maternal-fetal medicine.
History of seizure disorder. Even more conservative tapering (smaller increments, longer intervals) is warranted; abrupt discontinuation in this population carries the clearest documented seizure risk.

Clinical pearls

Taper over a minimum of 1 week per FDA labeling in all cases; extend to weeks-to-months for long-term, high-dose, or renally impaired patients.
Use percentage-based (hyperbolic) reductions rather than fixed mg steps once the dose falls below 150 mg/day, since receptor occupancy — and therefore symptom burden per mg removed — is nonlinear at lower doses.
Warn patients explicitly about seizure risk with missed doses or abrupt self-discontinuation; this is a labeled risk, not a theoretical one, and applies even to patients without epilepsy.
Reassess renal function (CrCl) before finalizing a taper schedule, and lengthen intervals proportionally in CKD.
When co-prescribed with opioids or benzodiazepines, taper sequentially rather than concurrently to isolate withdrawal attribution and reduce cumulative CNS depression risk during the transition.
Distinguish withdrawal (onset within 24–48 hours of a dose cut, plateauing within 1–2 weeks) from underlying disease relapse (gradual onset, no spontaneous plateau) before accelerating or reversing a taper.

For more clinician resources on safe deprescribing and tapering, visit tapermeds.com.

Tapering Pregabalin (Lyrica): Dose-Dependent Withdrawal and Seizure Risk